José Damas
External validation of the Dat'AIDS score: A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or older.
Hentzien M, Frossard J, Kouyos R, Prendki V, Damas J, Hofmann E, Braun D, Schmid P, Bernasconi E, Ragozzino S, Efthimiou O, Delpierre C, Allavena C, Bani-Sadr F, Calmy A, Swiss HIV Cohort Study S. External validation of the Dat'AIDS score: A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or older. HIV Med 2023; 25:72-82.
24.08.2023External validation of the Dat'AIDS score: A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or older.
24.08.2023HIV Med 2023; 25:72-82
Hentzien Maxime, Frossard Jaromil, Kouyos Roger D, Prendki Virginie, Damas José, Hofmann Eveline, Braun Dominique, Schmid Patrick, Bernasconi Enos, Ragozzino Silvio, Efthimiou Orestis, Delpierre Cyrille, Allavena Clotilde, Bani-Sadr Firouzé, Calmy Alexandra, Swiss HIV Cohort Study SHCS
Cerebrospinal Fluid HIV-1 Escape in Patients With Neurocognitive Symptoms: Pooled Data From a Neuro-HIV Platform and the NAMACO Study.
Filippidis P, Damas J, Viala B, Assal F, Tshikung O, Tarr P, Derfuss T, Oberholzer M, Jelcic I, Hundsberger T, Sacco L, Cavassini M, Du Pasquier R, Darling K, NAMACO Study Group, Swiss HIV Cohort Study. Cerebrospinal Fluid HIV-1 Escape in Patients With Neurocognitive Symptoms: Pooled Data From a Neuro-HIV Platform and the NAMACO Study. J Acquir Immune Defic Syndr 2023; 93:219-228.
01.07.2023Cerebrospinal Fluid HIV-1 Escape in Patients With Neurocognitive Symptoms: Pooled Data From a Neuro-HIV Platform and the NAMACO Study.
01.07.2023J Acquir Immune Defic Syndr 2023; 93:219-228
Filippidis Paraskevas, Damas José, Viala Benjamin, Assal Frédéric, Tshikung Olivier Nawej, Tarr Philip X00a0 E, Derfuss Tobias, Oberholzer Michael, Jelcic Ilijas, Hundsberger Thomas, Sacco Leonardo, Cavassini Matthias, Du Pasquier Renaud A, Darling Katharine Elizabeth Anna, NAMACO Study Group, Swiss HIV Cohort Study
Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus.
Jakeman B, Scherrer A, Darling K, Damas J, Bieler-Aeschlimann M, Hasse B, Schlosser L, Hachfeld A, Gutbrod K, Tarr P, Calmy A, Assal F, Kunze U, Stoeckle M, Schmid P, Rossi S, Di Benedetto C, Du Pasquier R, Cavassini M, Marzolini C, Hundsberger T. Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus. Open Forum Infect Dis 2022; 9:ofac457.
02.09.2022Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus.
02.09.2022Open Forum Infect Dis 2022; 9:ofac457
Jakeman Bernadette, Scherrer Alexandra U, Darling Katharine E A, Damas José, Bieler-Aeschlimann Melanie, Hasse Barbara, Schlosser Ladina, Hachfeld Anna, Gutbrod Klemens, Tarr Philip E, Calmy Alexandra, Assal Frédéric, Kunze Ursula, Stoeckle Marcel, Schmid Patrick, Rossi Stefania, Di Benedetto Caroline, Du Pasquier Renaud, Cavassini Matthias, Marzolini Catia, Hundsberger Thomas
Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV
Damas J, Hundsberger T, Di Benedetto C, Rossi S, Hasse B, Schlosser L, Du Pasquier R, Darling K, Cavassini M, Schmid P, Assal F, Ledergerber B, Nadin I, Tarr P, Stoeckle M, Kunze U, Hauser C, Gutbrod K, Calmy A, and the NAMACO study group. Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV. AIDS 2021; 35:2469-2480.
01.12.2021Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV
01.12.2021AIDS 2021; 35:2469-2480
Damas José, Hundsberger Thomas, Di Benedetto Caroline, Rossi Stefania, Hasse Barbara, Schlosser Ladina, Du Pasquier Renaud, Darling Katharine E A, Cavassini Matthias, Schmid Patrick, Assal Frédéric, Ledergerber Bruno, Nadin Isaure, Tarr Philip E, Stoeckle Marcel, Kunze Ursi, Hauser Christoph, Gutbrod Klemens, Calmy Alexandra, and the NAMACO study group